


## Ethyl azetidine-3-carboxylate hydrochloride

|                           |  |       |          |
|---------------------------|--|-------|----------|
| <b>Cat. No.:</b>          | HY-W052600                                       |       |          |
| <b>CAS No.:</b>           | 405090-31-5                                      |       |          |
| <b>Molecular Formula:</b> | C <sub>6</sub> H <sub>12</sub> ClNO <sub>2</sub> |       |          |
| <b>Molecular Weight:</b>  | 165.62   |       |          |
| <b>Target:</b>            | ADC Linker; PROTAC Linkers                       |       |          |
| <b>Pathway:</b>           | Antibody-drug Conjugate/ADC Related; PROTAC      |       |          |
| <b>Storage:</b>           | Powder   | -20°C | 3 years  |
|                           |  | 4°C   | 2 years  |
|                           | In solvent                                       | -80°C | 6 months |
|                           |  | -20°C | 1 month  |



### BIOLOGICAL ACTIVITY

|                                     |   |
|-------------------------------------|---|
| <b>Description</b>                  | Ethyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ethyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2]   |
| <b>IC<sub>50</sub> &amp; Target</b> | Non-cleavable   |
| <b>In Vitro</b>                     | ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

- [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov.* 2017;16(5):315-337.
- [2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-985.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA